It looks like a standard announcement guiding consensus downwards. According to my numbers consensus for FY21 EBITDA is $72.0m, so $58-$63m is downward guidance. Of course, in April no FY guidance was given, so we'll have to see the extent to which the SP which is 36% below consensus target already reflects this. Based on my reading there should not be a major SP movement, as the news is already in the SP. But the market doesn't always react rationally to news. This may present a buying opportunity to anyone who is looking to get in.
- Forums
- ASX - By Stock
- KGN
- Ann: May 2021 Business Update
Ann: May 2021 Business Update, page-7
-
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KGN (ASX) to my watchlist
(20min delay)
|
|||||
Last
$4.52 |
Change
0.070(1.57%) |
Mkt cap ! $451.7M |
Open | High | Low | Value | Volume |
$4.46 | $4.58 | $4.41 | $2.432M | 539.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
16 | 2458 | $4.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.53 | 13285 | 50 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 8843 | 4.520 |
17 | 14838 | 4.510 |
15 | 16166 | 4.500 |
15 | 15391 | 4.490 |
15 | 28066 | 4.480 |
Price($) | Vol. | No. |
---|---|---|
4.530 | 9416 | 34 |
4.540 | 5710 | 10 |
4.550 | 36600 | 18 |
4.560 | 6452 | 11 |
4.570 | 4683 | 8 |
Last trade - 15.56pm 15/07/2024 (20 minute delay) ? |
Featured News
KGN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online